-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Debate: PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors?

Sponsor: Education
Program: Spotlight Sessions
Hematology Disease Topics & Pathways:
Bleeding and Clotting, bleeding disorders, Diseases, Therapies
Sunday, December 10, 2023: 4:30 PM-5:45 PM
Room 29 (San Diego Convention Center)
Chair:
David Garcia, MD, University of Washington
Disclosures:
Garcia: Abbott: Other: Event adjudication committee member.
The participants in this debate will take the opposite sides of the question: should most patients with FXa-inhibitor-associated bleeding receive andexanet alpha (over prothrombin complex concentrates and/or best supportive care)? The session will include a detailed examination of the risks and the benefits of different managements strategies that may be considered for patients who are in this potentially precarious clinical situation.
PCC Should Be Used to Reverse Xai Anticoagulants

Sam Schulman, MD, PhD

Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada
Andexanet Should Be Used to Reverse Xai Anticoagulants

Deborah Siegal, MD, MSc

Department of Medicine, University of Ottawa, Ottawa, ON, Canada
See more of: Spotlight Sessions
<< Previous Session | Next Session >>